CTOs on the Move

Cellares

www.cellares.com

 
Cellares is revolutionizing cell therapy manufacturing. We are developing a one-of-a-kind solution, The Cell Shuttle, to overcome the challenges associated with manufacturing so these life-saving therapies are affordable and widely available to patients who can benefit.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.cellares.com
  • 345 Allerton Ave
    South San Francisco, CA USA 94080
  • Phone: 833.235.5273

Executives

Name Title Contact Details

Funding

Cellares raised $18M on 10/29/2020
Cellares raised $832M on 05/05/2021

Similar Companies

Synspira

Synspira Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to significantly improving the lives of people with cystic fibrosis (CF) and other rare diseases.

Wheeler Bio

A disruptive new biopharmaceutical CDMO, we are pushing the boundaries of biomanufacturing and solving an outdated industry bottleneck with a unique partnering model. By bringing together biologics drug innovators, discovery CROs, and CDMOs, we are accelerating the translation of therapeutic innovation to clinical impact.

CordenPharma

CordenPharma is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dyne Therapeutics

Dyne was founded with a singular focus: to transform the lives of people with serious muscle diseases by pioneering muscle-targeted therapies. Our proprietary technologies provide the foundation for breakthrough treatments. We have assembled a world-class team of experts who are united by their commitment to fulfill this mission.

Omega Therapeutics

Omega Therapeutics is a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform. The OMEGA™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism`s life from cell genesis, growth and differentiation to cell death. The OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega`s engineered, modular, and programmable mRNA-encoded epigenetic medicines, Omega Epigenomic Controllers™, target specific intervention points amongst the thousands of mapped and validated novel DNA-sequence-based epigenomic loci to durably tune single or multiple genes to treat and cure disease through Precision Genomic Control™. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.